#Switzerland #RNA Therapeutics #Basel #Versameb #signal peptides

Versameb AG Receives First Patent in China for Groundbreaking Signal Peptide Technology

Basel, Switzerland, March 20, 2025 — Versameb AG, a clinical-stage biotech firm dedicated to transforming RNA-based therapeutics, has exciting news! The company has announced the receipt of a Notice of Allowance for its first patent in China, focusing on its innovative signal peptide technology. This achievement marks a pivotal moment in Versameb's ongoing mission to advance RNA therapeutics aimed at addressing significant unmet medical needs worldwide.

The newly issued patent covers proprietary technology that employs signal peptides to elevate the delivery and expression of heterologous proteins. This advancement holds immense potential across various therapeutic domains. The technology is integrated into Versameb's VERSagile platform, aimed at maximizing the effectiveness and potency of RNA therapeutics.

This patent is particularly significant for Versameb's flagship compound, VMB-100, which is currently in development for stress urinary incontinence (SUI). Klaas Zuideveld, the CEO of Versameb AG, expressed enthusiasm regarding this milestone: "We are delighted to secure this patent in China, which underscores the innovative character of our technology. It also reinforces our standing in the swiftly evolving realm of RNA therapeutics. This achievement is a clear indication of our team’s commitment to creating cutting-edge solutions for unmet medical demands. We eagerly anticipate using this technology to push our development pipeline and deliver novel therapy options to patients globally."

The granting of this patent demonstrates a substantial step forward for Versameb as it continues to enhance its global presence and protect its groundbreaking technologies. The company maintains a steadfast commitment to progressing its research and development initiatives aimed at introducing transformative RNA-based therapies to the market.

About VMB-100

VMB-100 is an innovative intramuscular mRNA treatment that encodes human IGF-1, specifically targeting the treatment of stress urinary incontinence. The compound has exhibited great promise in promoting sustained muscle regeneration with only short-term administration. Preclinical studies have shown that VMB-100 significantly increases IGF-1 expression in human muscle cells while speeding up urinary sphincter muscle regeneration in animal models of SUI. Additionally, the FDA has recently cleared the IND application for VMB-100, setting the stage for a Phase 2a dose-ascending study targeting moderate SUI in women, slated for 2025.

Understanding Stress Urinary Incontinence

Stress urinary incontinence is a common issue affecting many women, characterized by the unexpected leakage of urine during physical exertion due to a weakened urinary sphincter muscle. As the most prevalent form of urinary incontinence, it impacts 86% of women with incontinence. In fact, it is estimated that over 30% of adult women globally experience SUI. Unfortunately, despite its vast prevalence, there are currently no approved pharmacological treatments for SUI available in the United States. Existing treatment options are limited to short-term solutions such as pelvic floor therapy or invasive surgical procedures, which include the permanent implantation of a sling in the urethra or bladder neck.

About Versameb AG

Founded in Basel in 2018, Versameb AG is a privately-owned biotechnology firm devoted to discovering and developing pioneering RNA-based therapeutics. The company’s leadership team comprises seasoned scientists and industry veterans with a wealth of expertise in the drug discovery process, from laboratory settings to patient care. Utilizing its proprietary VERSagile technology platform, Versameb seeks to optimize the application of functional RNA across various disease contexts. The platform promotes the modulation of protein expression, fostering simultaneous interactions with multiple targets within a single molecule, ensuring accurate cellular targeting. Versameb's development pipeline includes promising candidates for urology, solid tumors, and rare diseases. The company aspires to complete its inaugural human proof-of-concept clinical study and is dedicated to advancing its innovative platform. For more details about Versameb, visit www.versameb.com and connect on LinkedIn.